Adaptimmune Therapeutics (NASDAQ:ADAP) Given "Sell (E+)" Rating at Weiss Ratings

Key Points

• Adaptimmune Therapeutics received a "sell (e+)" rating from Weiss Ratings, amid various adjustments from other analysts including a cut from "outperform" to "neutral" by Mizuho.
• The company's stock has recently seen a significant increase of 42.1%, trading at $0.20, with a market capitalization of approximately $52.21 million.
• Adaptimmune posted quarterly earnings that beat estimates, reporting $13.68 million in revenue and a loss per share of ($0.11).

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report)'s stock had its "sell (e+)" rating reissued by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

ADAP has been the subject of several other reports. HC Wainwright reaffirmed a "neutral" rating on shares of Adaptimmune Therapeutics in a research note on Tuesday, July 29th. Mizuho cut shares of Adaptimmune Therapeutics from an "outperform" rating to a "neutral" rating and reduced their price objective for the company from $1.50 to $0.50 in a report on Thursday, June 26th. Finally, Guggenheim cut shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 29th. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Adaptimmune Therapeutics has a consensus rating of "Reduce" and an average price target of $1.35.

Adaptimmune Therapeutics Stock Up 42.1%

ADAP traded up $0.06 during midday trading on Wednesday, hitting $0.20. The company had a trading volume of 403,193,001 shares, compared to its average volume of 29,173,092. Adaptimmune Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.91. The company has a market capitalization of $52.21 million, a price-to-earnings ratio of -0.30 and a beta of 2.49. The stock's 50 day moving average price is $0.09 and its 200 day moving average price is $0.20.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative net margin of 260.82% and a negative return on equity of 163.73%. The firm had revenue of $13.68 million during the quarter, compared to the consensus estimate of $11.04 million. Research analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Insiders Place Their Bets

In other Adaptimmune Therapeutics news, Director Ali Behbahani sold 14,671,794 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $0.01, for a total value of $146,717.94. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 19,803,000 shares of company stock worth $198,030 in the last 90 days. 12.44% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP boosted its stake in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares during the last quarter. Empirical Finance LLC purchased a new position in Adaptimmune Therapeutics in the second quarter valued at about $192,000. Acadian Asset Management LLC boosted its stake in Adaptimmune Therapeutics by 334.8% in the first quarter. Acadian Asset Management LLC now owns 2,218,215 shares of the biotechnology company's stock valued at $424,000 after acquiring an additional 1,707,999 shares during the last quarter. Two Seas Capital LP boosted its stake in Adaptimmune Therapeutics by 38.4% in the first quarter. Two Seas Capital LP now owns 20,529,685 shares of the biotechnology company's stock valued at $4,044,000 after acquiring an additional 5,694,539 shares during the last quarter. Finally, Long Focus Capital Management LLC boosted its stake in Adaptimmune Therapeutics by 15.9% in the first quarter. Long Focus Capital Management LLC now owns 23,756,687 shares of the biotechnology company's stock valued at $4,680,000 after acquiring an additional 3,262,294 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.